<DOC>
	<DOC>NCT01709994</DOC>
	<brief_summary>The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).</brief_summary>
	<brief_title>Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients</brief_title>
	<detailed_description>Hypothesis: The low-dose aspirin reduces cardiovascular risk in patients with chronic kidney disease without increasing the risk of bleeding</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>sign informed consent males 4579 years or females 5579 years. Stage 3 or 4 CKD (estimated GFR by MDRD abbreviated, between 15 and 60 ml / min/1.73 m2) a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular arteriopathy documented hospitalization for any cause in the last three months prior to inclusion in the study allergy of acetylsalicylic acid coagulopathy from any cause thrombocytopenia &lt;150,000 platelets liver disease from any cause Infection by hepatitis B virus, hepatitis C or HIV immunosuppressive treatment within 12 weeks before inclusion in the study Major bleeding events including gastrointestinal bleeding and brain hemorrhage. hemoglobinopathies (eg sickle cell disease or thalassemia of any kind) active malignancy (except nonmelanoma skin cancer). May be included in the study patients with malignant neoplasia who have remained diseasefree for at least the previous 5 years. uncontrolled inflammatory disease or symptomatic (eg rheumatoid arthritis, lupus, Chrom disease or bowel inflammatory disease) hemolysis treatment with oral anticoagulation and / or antiplatelet therapy prior. poorly controlled hypertension (&gt; 160/90 mm Hg) pregnancy or breast women of childbearing potential not using effective contraception.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>cardiovascular events</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>bleedings</keyword>
	<keyword>progression</keyword>
	<keyword>antiinflammatory effects</keyword>
</DOC>